← All earnings call summaries
IOL Chemicals and Pharmaceuticals Limited — Q1FY27 Earnings Call Summary
Key Takeaways
- New CDMO facility with 1,500 mn tablets capacity, EU GMP certified, commercializing Q3 FY27
- Initiatives expected to add 25-30% incremental top line by FY29
- Ibuprofen asset turns ~1.75x; optimal utilization >80% by FY29
- CDMO margins expected better than API; optimal utilization in 18-24 months
- ROCE from projects expected ~15% at steady state
- Ibuprofen capacity expansion by 6,000 MTPA to 18,000 MTPA, commissioning by Dec 2027
- Capex funded fully from internal accruals; 30% already spent
- Ibuprofen prices stable; backward integration controls raw material cost
- Announced INR 500 Cr investment in three strategic growth initiatives
- Specialty chemical facility under tolling arrangement with global customer
📄 Source: View original transcript (PDF)
Get IOL Chemicals and Pharmaceuticals Limited earnings summaries on Telegram
Add IOL Chemicals and Pharmaceuticals Limited to your watchlist. Receive AI-generated summaries within hours of every earnings call.
Start free →
Summary generated by AI from the official transcript filed on BSE/NSE. Not investment advice.